Clinical Trial Update: Study of Atezolizumab in Advanced Non-oncogene-addicted NSCLC With PD-L1 ≥50%, Including Longitudinal c-FLIP Assessment in Monocytic MDSCs.

View source ↗

Summary

A study evaluating atezolizumab in PD-L1 high advanced non-small cell lung cancer with correlative c-FLIP analysis in monocytic myeloid-derived suppressor cells…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tecentriq (atezolizumab)

Snippet

Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Conditions: Non Small Cell Lung Cancer | Status: NOT_YET_RECRUITING